Frequently Asked Questions: The COVAX Humanitarian Buffer

This FAQ document has been prepared by the IASC Working Group on COVID-19 vaccines. The Working Group was tasked by the IASC Emergency Directors Group to work with Gavi, the Vaccine Alliance, on the establishment of the COVAX Humanitarian Buffer. These FAQs are intended for all IASC entities, humanitarian partners, and external stakeholders. The FAQs will be updated and re-circulated as required to ensure they reflect the most relevant and up-to-date information.

GENERAL

1. What is the COVAX Humanitarian Buffer?
The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of ‘last resort’ to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. The Humanitarian Buffer is only to be used where there are unavoidable gaps in coverage in national vaccination plans and micro-plans, despite advocacy efforts.

National governments are responsible for ensuring access to COVID-19 vaccines for all people within their respective territory. The ‘first resort’ for all populations of concern, irrespective of legal status, is that they are included in national vaccination plans and reached during the implementation of those plans. Gavi, IASC partners, civil society and others will continue to advocate with national governments to ensure the inclusion of all populations regardless of their legal status in line with the WHO Strategic Advisory Group of Experts on Immunization (SAGE) ‘Values Framework’ and ‘Roadmap For Prioritizing Uses Of COVID-19 Vaccines in The Context Of Limited Supply’ and will advocate for the revision of national plans and micro-plans if required.

2. Has the Humanitarian Buffer been operationalized? When will doses from the Humanitarian Buffer become available?
The Humanitarian Buffer is expected to be operational and ready to receive applications from May 2021.

3. How many doses are available through the Humanitarian Buffer?
The COVAX Buffer includes both the Humanitarian Buffer and the Contingency Provision (see question 5). Up to 5% of the COVAX Facility’s real-time doses will be made available to the COVAX Buffer as they become available. This 5% could reach up to 100 million doses by the end of 2021, recognizing that the Humanitarian Buffer is a flexible and demand-driven mechanism. Doses delivered to a country through the Humanitarian Buffer will be in addition to any standard country allocations through the COVAX Facility (i.e. a ‘top up’).

4. In what scenarios is it envisaged the Humanitarian Buffer will be used?
Gavi and IASC partners continue to advocate for the inclusion of populations of concern that are at risk of exclusion from national vaccination plans and micro-plans. However, we anticipate there will be four broad scenarios in which the Humanitarian Buffer will need to be used:

   i. National authorities are unwilling to include populations of concern in their national plans despite high-level advocacy.

   ii. National authorities include populations of concern in their national vaccination plans, but the subsequent micro-planning process and/or implementation process highlights an unwillingness or inability to support vaccination for these groups.
iii. National authorities do not have full control over all or parts of their territory and have no access to populations of concern in certain locations.

iv. An unforeseen humanitarian crisis (e.g. a cross-border displacement or natural disaster) that occurs after the finalization of the national vaccination planning process and requires a national authority to receive a ‘top-up’ of additional doses. In such a scenario, a national government will be asked to clearly demonstrate why the population of concern cannot be vaccinated through national planning processes and standard COVAX allocations, rather than the Humanitarian Buffer.

5. **What is the difference between the COVAX Contingency Provision and the COVAX Humanitarian Buffer?**

The COVAX Buffer will comprise of two components: The Humanitarian Buffer and the Contingency Provision. The Contingency Provision will provide an emergency release of doses to help mitigate the most severe clusters of high mortality where normal vaccine allocation timelines may not be sufficient. The Contingency Provision is not yet operational and will be designed and implemented at a later stage. Until the Contingency Provision comes into effect, all doses that are made available for the COVAX Buffer will be for the Humanitarian Buffer.

**POPULATIONS OF CONCERN FOR THE HUMANITARIAN BUFFER**

6. **Which groups are considered as populations of concern for the Humanitarian Buffer?**

Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status.

7. **What is the estimated size of the populations of concern?**

The IASC estimates there are approximately 167 million people at risk of exclusion from COVID-19 vaccination, noting that these numbers are highly variable and subject to change due to unexpected shocks (such as conflicts, natural disasters etc.). The current number of refugees, IDPs and stateless populations is over 80 million. Even in the ideal scenario of all countries including all populations of concern in their national plans, it is estimated that 60-80 million people in non-government-controlled areas could remain beyond national authorities’ reach.

These estimates are based on data from the 2021 Global Humanitarian Overview (GHO). However, the populations of concern for the Humanitarian Buffer will not be limited to populations in the 2021 GHO. The Humanitarian Buffer is designed to be flexible and agile to respond to dynamic situations and risks of exclusion, and can be used to reach any population of concern in a humanitarian setting that is not being vaccinated by national authorities, regardless of whether or not they are included in the 2021 GHO.

8. **How will populations of concern be prioritized? Will the Humanitarian Buffer vaccinate everyone caught up in humanitarian crises?**

The Humanitarian Buffer is neither designed nor intended to cover the entirety of populations of concern, nor to prioritize them over any other population. In line with WHO SAGE guidelines and to ensure parity with the standard COVAX vaccine rollout in a specific country, the Humanitarian Buffer only intends to provide enough doses for high-risk groups within a given population of concern to cover frontline healthcare workers, the medically vulnerable, and those who meet nationally set age criteria. Based on IASC estimates, 20% of the 167 million people at risk of exclusion from COVID-19 vaccination...
would account for approximately 33 million people. Assuming a two-dose regimen, this would mean that a rough, indicative planning assumption would be that 66 million doses would be required for the Humanitarian Buffer.

9. Does the establishment of the Humanitarian Buffer create an incentive for national authorities to exclude populations of concern from their national vaccination plans? Through continued advocacy at all levels, Gavi and IASC partners are encouraging national authorities to include populations of concern in their national plans and micro-plans, in line with the main provisions of UN Security Council resolution 2565 (2021). National Deployment and Vaccination plans should be updated and uploaded to the Partner Platform by the national governments and should include populations of concern. Moreover, given the limited number of doses available to the Humanitarian Buffer, applications to the Humanitarian Buffer will need a strong justification for why a population of concern has not been included in a national vaccination plan.

10. What advocacy have you undertaken to ensure that populations of concern are included in national vaccination plans? IASC agencies consistently brief their respective country representatives on the importance of advocating with national authorities to include populations of concern. Review and monitoring of national vaccination plans for inclusion of populations of concern is taking place at country, regional and global level, and targeted advocacy is undertaken based on these reviews. We have also held a senior-level dialogue with Humanitarian Coordinators to emphasize their role in advocacy. Gavi and IASC partners will continue to work closely with operational partners in-country to monitor the implementation of national vaccination plans and micro-plans to ensure the inclusion of populations of concern.

11. Do you envisage a situation in which a population of concern has better access to COVID-19 vaccines than other groups in that country? One of the key principles that will guide allocation through the Humanitarian Buffer is ‘contextual parity’. This means that the allocation process will be sensitive to intra- and inter-country disparities and ensure there is no privileged access or improper prioritization of one population or country over another.

12. Will UN and NGO staff be vaccinated through the Humanitarian Buffer? No. The UN is implementing its own system-wide vaccination effort for its staff and UN implementing partners in duty stations in which they cannot receive vaccinations from the host governments.

WHO CAN APPLY FOR DOSES THROUGH THE HUMANITARIAN BUFFER?

13. Can national governments apply to receive doses from the Humanitarian Buffer? Both national governments (as long as they are COVAX participants) and humanitarian agencies can apply for buffer doses. However, if a national government applies, they will be asked to clearly demonstrate why the population of concern for which they are applying for doses were not included in national vaccination plans and what other attempts have been made to cover them. (e.g. a recent cross-border displacement after the submission of the national vaccination plan).

14. Can Humanitarian Agencies apply to receive doses from the Humanitarian Buffer? Yes. All national and international humanitarian agencies will be eligible to apply to the Humanitarian Buffer, including UN agencies, ICRC, IFRC, National Red Cross and Red Crescent Societies, and civil
society organizations (as long as they meet the eligibility criteria to apply set out in the COVAX Humanitarian Buffer Application). Humanitarian agencies will be asked to demonstrate that there is a clear, demonstrable gap in vaccine coverage, that the agency is able to access the population of concern in question, and that they have both the experience and the necessary competence to deliver successful vaccination campaigns in a humanitarian setting. Contextual parity will also be a key consideration in decision-making for allocations to the Humanitarian Buffer (see question 14 above).

15. Can both AMC-eligible and Self-Financing Participants receive doses through the Humanitarian Buffer?
Both Advanced Market Commitment (AMC)-eligible countries and territories and self-financing countries and territories participating in COVAX can receive doses from the Humanitarian Buffer. Both self-financing countries and AMC countries and territories will receive these doses as an addition ('top-up) to their COVAX Facility allocation.

16. Will the COVAX Facility finance the costs of doses through the Humanitarian Buffer to both AMC-eligible countries and Self-Financing Participants?
For AMC-eligible countries, the cost of the doses allocated through the Humanitarian Buffer will be financed by the Gavi COVAX AMC. For self-financing participants of the COVAX Facility the cost of the doses will have to be borne by the country. Some exceptions could be considered if the doses allocated will be delivered to a population that originates from an AMC country or territory. Decisions on financing of Humanitarian Buffer doses for self-financing countries and territories will be taken on a case-by-case basis.

17. Will applicants have a choice over the type of vaccine they will receive?
No. The choice of vaccine allocated in each context will be based on available supply, regulatory landscape, and the readiness of the specific country/territory to administer a certain type of vaccine. A primary consideration is for the vaccines to be those already in use in the country so that indemnity and liability agreements are already in place. All vaccines delivered through the COVAX Humanitarian Buffer will have received WHO Emergency Use Listing/Prequalification.

DECISION-MAKING FOR ALLOCATIONS

18. What is the role of the Inter-Agency Standing Committee (IASC) in decisions on buffer allocations?
The Gavi Board has delegated decision making on Humanitarian Buffer doses to the IASC Emergency Directors Group (EDG). This process has been designed to ensure that humanitarian experts are involved in decision-making so that doses are appropriately prioritized, and judgements on the feasibility of delivery to populations of concern are made by those with experience of vaccination campaigns in humanitarian settings. An expert “decision group” reporting to the IASC EDG has been established to take decisions on allocations to the Humanitarian Buffer. Decision-making will be guided by the humanitarian principles of neutrality, impartiality, independence, and humanity.

19. How will Humanitarian Buffer allocation decisions be made?
A decision group comprising experts from IASC entities has been established to take decisions on allocations to the buffer and will report to the IASC EDG. They will receive secretariat support from the Joint Allocation Taskforce (JAT) of the COVAX Facility. A UN Country Team, Humanitarian Country Team, or equivalent will receive the requesting entity’s request and provide an opinion as to whether or not the request meets the eligibility criteria (see above question 14). The decision group will only consider
requests by humanitarian agencies which meet the eligibility criteria to apply and have been approved by the Resident/ Humanitarian Coordinator (or equivalent senior official) if appropriate.

The decision group will decide by consensus, based on the information provided. If, in exceptional circumstances, the decision group cannot reach consensus, it may refer the request to the Emergency Directors’ Group (EDG) for input before deciding. The final decision remains with the decision group. A request form and a ‘process description’ document along with relevant guidelines is currently in preparation. The applications will be received on a rolling basis. Decisions taken by the decision group will be final.

20. Which agencies are part of the IASC decision group?
The decision group will comprise of up to 10 IASC agencies: WHO, UNICEF, OCHA, IOM, UNHCR, ICRC, IFRC, MSF and a representative from the IASC’s NGO consortia. Gavi will be an observer. WHO will chair the decision group.

21. Who does the decision group report to?
The decision group reports to the IASC EDG. The decision group will provide the Gavi Board with twice yearly reporting on the allocations through the buffer.

22. How quickly will allocation decisions be taken?
Once the decision group receives all the required information related to a request and the application is complete, the body will decide within a maximum of 5 working days. The JAT Secretariat will then inform the requesting entity of the decision, and if the request has been approved, the process of delivery of the vaccines will begin.

FINANCING OF DELIVERY COSTS

23. What are the unit costs of COVID-19 vaccine delivery in humanitarian settings?
The cost of delivery refers to the cost of administering the vaccines once they have arrived in a country. The cost of delivery will vary from country to country based on several factors. A COVAX working group estimated it would cost around $1.66 per dose in a stable and relatively well-developed setting. It is expected that the cost will likely be higher in fragile and conflict-affected settings. IASC partners are currently working to develop a more accurate estimate for delivery costs in fragile and humanitarian settings.

24. Does the COVAX Facility/ Gavi cover the costs of vaccine delivery?
For Humanitarian Buffer doses financed through the Gavi COVAX AMC, Gavi will cover the cost of doses and their shipment to the designated port of entry. Gavi has set aside US $7.5m to finance delivery costs in exceptional cases where other funding is not available. However, US $7.5m is unlikely to be enough to cover all the costs associated with the delivery of doses through the Humanitarian Buffer, and additional resources will need to be mobilized, especially to cover delivery costs to remote or otherwise hard-to-reach locations.

25. How will delivery costs for the Humanitarian Buffer be financed? How can a donor finance delivery costs for buffer doses?
Several IASC partners have launched or plan to launch appeals to fundraise for the costs of COVID-19 vaccine delivery. The majority of the resources mobilized through these appeals will cover the costs of delivery for vaccine doses that have not been allocated through the Humanitarian Buffer. Doses
allocated through the COVAX Facility to countries (i.e. non-buffer doses) will constitute the bulk of COVID-19 vaccine delivery in humanitarian settings.

For Humanitarian Buffer dose allocations, the IASC partners are currently exploring options to streamline financing mechanisms for delivery costs to allow for the rapid transfer of funds to the implementing agency, should that be required.

26. Will COVID-19 vaccine delivery in humanitarian settings impact on the delivery of other humanitarian assistance?
It is crucial to sustain financing to core humanitarian activities, including routine vaccinations and enabling activities such as community mobilization and engagement (which are as critical to successful vaccination activities as vaccine delivery itself). The international humanitarian system is facing an unprecedented level of humanitarian needs. COVID-19 may not be the most acute public health or humanitarian issue facing countries with humanitarian crises. Financing for COVID-19 vaccines must not come at the expense of other humanitarian activities, and operational capacities should not be diverted from other priorities. Additional resources will be required to meet the costs of COVID-19 vaccine delivery.

27. Could the World Bank and Regional Development Banks cover delivery costs for the Humanitarian Buffer?
The World Bank and other regional development banks have pledged to support national authorities with preparedness, readiness, and vaccine delivery. The World Bank pledged $12 billion in October 2020 to support countries with their COVID-19 response. This includes vaccine delivery, but also procurement of vaccines, testing, diagnostics, and therapeutics. We do not have clarity yet whether any of these funds could be used to finance delivery costs from doses allocated through the Humanitarian Buffer. The World Bank has indicated that they would be willing to channel financing through “partner organizations”, with the agreement of the national government. It should also be noted that several countries in the GHO are not eligible to receive World Bank funding.

28. Do you plan to launch another Global Humanitarian Response Plan, amend the GHO or launch a new consolidated appeal to integrate the costs of vaccine delivery?
No. We do not intend to launch a new GHRP, or adjust the GHO, or launch a new consolidated appeal in 2021.

29. Will Humanitarian Response Plans or Refugee Response Plans need to be adjusted to incorporate vaccine delivery costs?
The decision on which planning tool is the most appropriate to support Humanitarian Buffer dose delivery will need to be considered on a case-by-case basis.

MONITORING AND EVALUATION

30. How will monitoring and evaluation and learning be undertaken for Humanitarian Buffer doses?
Countries, territories, and humanitarian agencies that receive doses through the Humanitarian Buffer will be responsible for reporting on their use. When applying for Humanitarian Buffer doses, applicants will be required to provide information on specific metrics within a specified timeframe following the implementation. UNCTs/HCs/RCs, and Health Clusters/Sectors will also support monitoring at country-
level. With secretariat support from the JAT, the decision group will ensure that lessons learned are incorporated into its decision making.

INDEMNITY AND LIABILITY

Please note that more detailed advice on liability and compensation issues related to the COVAX Humanitarian Buffer will be made available as soon as possible.